[Medical economics evaluation of 5-HT3 receptor antagonist drugs].
At Komaki City Hospital, the drug cost in connection with cancer chemotherapy was re-examined as part of improved management along with the introduction of DPC in July 2008. With due attention to the 5-HT3 receptor antagonists, both the change from injections to oral drugs and the change from brand-name drugs to generic drugs were tried between July 2008 and June 2009. After that, in order to examine the economic impact of these changes, we investigated and analyzed the number of medications, the cost of medicine purchased, and the average drug cost per medication of the 5-HT3 receptor antagonists between April 2008 and September 2009. As a result, the cost of 5-HT3 receptor antagonists purchased decreased greatly, and the impact of the improvement was mainly due to the change to oral drugs, and partially to the change to generic drugs. Therefore, from the viewpoint of hospital economic improvement in DPC, it was thought that the change to oral drugs(5-HT3 receptor antagonists)is given top priority.
Utsunomiya
Junpei
J
Department of Pharmacy, Komaki City Hospital.
Hirano
Shigeki
S
Fukui
Aiko
A
Funabashi
Kazuaki
K
Deguchi
Yuko
Y
Yamada
Susumu
S
Naito
Kazuyuki
K
D000284:Administration, Oral; D000932:Antiemetics / Q000008:administration & dosage / Q000191:economics*; D000970:Antineoplastic Agents / Q000009:adverse effects; D004470:Economics, Medical; D058831:Serotonin 5-HT3 Receptor Antagonists
D000932:Antiemetics; D000970:Antineoplastic Agents; D058831:Serotonin 5-HT3 Receptor Antagonists